Gensaic: redosable, large-capacity gene therapies

Gensaic is developing redosable gene-delivery vectors comprising particles derived from a bacteriophage that resides in the human gut. The company says the M13 bacteriophage can be engineered to target specific tissues and overcome the capacity, immunogenicity and manufacturing difficulties associated with AAVs.

Gensaic’s investors include Ovid Therapeutics Inc. (NASDAQ:OVID) and the Cystic Fibrosis Foundation, and it is operating out of Cambridge, Mass.-based incubator LabCentral. ...